Evicenter
Zepbound (tirzepatide) in Chronic weight management
Manufacturer
Lilly USA, LLC
Prescribing information
Zepbound (opens in a new tab)
Questions
33
Last updated

All questions

Safety: Zepbound (tirzepatide) in chronic weight management

9 questions · 3 sources

Side effects

Zepbound vs Wegovy: how do the side effects compare (SURMOUNT-5)?

“Table depicting adverse reactions that occurred in ≥5% of participants in at least one of the treatment groups: Zepbound MTD (10 mg or 15 mg) (n=374) or Wegovy MTD (1.7 mg or 2.4 mg) (n=376). 43.6% of participants taking Zepbound and 44.4% of participants taking Wegovy experienced nausea. 27.0% of participants taking Zepbound and 28.5% of participants taking Wegovy experienced constipation. 23.5% of participants taking Zepbound and 23.4% of participants taking Wegovy experienced diarrhea. 15.0% of participants taking Zepbound and 21.3% of participants taking Wegovy experienced vomiting. 13.6% of participants taking Zepbound and 12.5% of participants taking Wegovy experienced COVID-19. 10.4% of participants taking Zepbound and 12.2% of participants taking Wegovy experienced fatigue. 9.9% of participants taking Zepbound and 7.7% of participants taking Wegovy experienced eructation. 8.6% of participants taking Zepbound and 0.3% of participants taking Wegovy experienced injection site reaction. 8.6% of participants taking Zepbound and 11.4% of participants taking Wegovy experienced upper respiratory tract infection. 8.3% of participants taking Zepbound and 6.1% of participants taking Wegovy experienced hair loss. 7.2% of participants taking Zepbound and 6.4% of participants taking Wegovy experienced abdominal distention. 7.2% of participants taking Zepbound and 7.2% of participants taking Wegovy experienced headache. 6.4% of participants taking Zepbound and 6.9% of participants taking Wegovy experienced abdominal pain. 6.4% of participants taking Zepbound and 4.8% of participants taking Wegovy experienced dizziness. 6.1% of participants taking Zepbound and 10.6% of participants taking Wegovy experienced gastroesophageal reflux disease. 5.9% of participants taking Zepbound and 7.4% of participants taking Wegovy experienced dyspepsia. 4.5% of participants taking Zepbound and 5.1% of participants taking Wegovy experienced decreased appetite. 4.5% of participants taking Zepbound and 6.1% of participants taking Wegovy experienced nasopharyngitis. 2.9% of participants taking Zepbound and 5.6% of participants taking Wegovy experienced sinusitis.” (opens the source at this quote in a new tab)

On the page, select: Show description

Note: SURMOUNT-5 results are from the clinical data page of the Zepbound HCP site; the Zepbound Prescribing Information does not describe this trial.

What are the most common side effects of Zepbound?

Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients). The clinical data page of the Zepbound HCP site presents the same pooled rates as SURMOUNT-1 and SURMOUNT-2.

How common is nausea on Zepbound?

Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients).

Does Zepbound nausea go away?

Note: The first passage is from the pooled Study 1 and Study 2 results of the Prescribing Information. The second is from SURMOUNT-MAINTAIN on the clinical data page of the Zepbound HCP site; the Prescribing Information does not describe that trial.

How can Zepbound nausea and stomach side effects be reduced?

Note: The eating suggestions are from the dosing page of the Zepbound HCP site, which cites published reviews of medication-related nausea and GLP-1 receptor agonist use; they do not appear in the Prescribing Information.

How many people stop taking Zepbound because of side effects?

What are the long-term side effects of Zepbound (SURMOUNT-MAINTAIN)?

“Table showing the adverse events that emerged during treatment and occurred in ≥5% of participants in any treatment group in SURMOUNT-MAINTAIN. Deaths occurred in <1% of participants taking Zepbound MTD (10 mg or 15 mg) (n=441) from week 0 to week 60. From week 60 to week 112, deaths occurred in 0% of patients who received Zepbound MTD (10 mg or 15 mg) (n=139), who had their dose reduced to Zepbound 5 mg (n=142), or who were switched to placebo (n=91). From week 0 to week 60, participants taking Zepbound MTD (10 mg or 15 mg) (n=441) experienced: nausea: 35%, vomiting: 17%, diarrhea: 24%, constipation: 31%, eructation: 8%, dyspepsia: 7%, gastroesophageal reflux disease: 7%, abdominal pain: 6%, abdominal distension: 5%, upper respiratory tract infection: 7%, COVID-19: 7%, influenza: 5%, sinusitis: 3%, urinary tract infection: 3%, injection site reaction: 9%, fatigue: 10%, headache: 9%, dizziness: 7%, decreased appetite: 5%, and alopecia: 9%. Participants taking Zepbound MTD (10 mg or 15 mg) (n=139) experienced from week 60 to week 112: nausea: 6%, vomiting: 6%, diarrhea: 7%, constipation: 1%, eructation: 3%, dyspepsia: 2%, gastroesophageal reflux disease: 1%, abdominal pain: 1%, abdominal distension: 3%, upper respiratory tract infection: 1%, COVID-19: 1%, influenza: 4%, sinusitis: 5%, urinary tract infection: 5%, injection site reaction: 6%, fatigue: 1%, headache: 2%, dizziness: 1%, decreased appetite: 0%, and alopecia: 1%. Participants who had their dose reduced to Zepbound 5 mg (n=142) experienced from week 60 to week 112: nausea: 4%, vomiting: 1%, diarrhea: 5%, constipation: 4%, eructation: 1%, dyspepsia: 1%, gastroesophageal reflux disease: 1%, abdominal pain: 1%, abdominal distension: 1%, upper respiratory tract infection: 4%, COVID-19: 3%, influenza: 1%, sinusitis: 5%, urinary tract infection: 1%, injection site reaction: 2%, fatigue: 0%, headache: 4%, dizziness: 1%, decreased appetite: 0%, and alopecia: 0%. Participants who were switched to placebo (n=91) experienced from week 60 to week 112: nausea: 2%, vomiting: 0%, diarrhea: 1%, constipation: 4%, eructation: 0%, dyspepsia: 0%, gastroesophageal reflux disease: 1%, abdominal pain: 0%, abdominal distension: 1%, upper respiratory tract infection: 2%, COVID-19: 0%, influenza: 4%, sinusitis: 0%, urinary tract infection: 0%, injection site reaction: 0%, fatigue: 0%, headache: 3%, dizziness: 0%, decreased appetite: 0%, and alopecia: 0%.” (opens the source at this quote in a new tab)

On the page, select: Show description

Note: SURMOUNT-MAINTAIN is not described in the Zepbound Prescribing Information.

Does Zepbound cause hair loss?

Note: Table 1 columns are placebo, ZEPBOUND 5 mg, 10 mg, and 15 mg, in that order (% of patients).

Does Zepbound increase heart rate?